Trial · NCT07903220
A Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada
NCT07903220, Not yet recruiting, Takeda
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada. Trials, record NCT07903220. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903220
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada
- NCT number
- NCT07903220
- Status
- Not yet recruiting
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Takeda
- Conditions
- Narcolepsy Type 1
- Interventions
- No intervention
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes53
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Retrospective Cohort: Percentage of Participants in Each Treatment Sequence | From diagnosis of NT1 up to enrollment (baseline) [approximately past 5 years from enrollment] | |
| Primary | Retrospective Cohort: Percentage of Participants Who Permanently Discontinued Treatment, Switched Treatment, or Experienced a Change in Treatment Dose | From diagnosis of NT1 up to enrollment (baseline) [approximately past 5 years from enrollment] | |
| Primary | Prospective Cohort: Number of Participants With Permanent Discontinuation, Switch, Interruptions, or Changes in Treatment Dose and Related Reasons | Prospective Cohort: Up to 24 weeks | |
| Primary | Retrospective Cohort and Prospective Cohort: Average Duration on Treatment | Retrospective Cohort: From diagnosis of NT1 up to enrollment (baseline) [approximately past 5 years from enrollment]; Prospective Cohort: Up to 24 weeks | |
| Primary | Retrospective Cohort and Prospective Cohort: Time to Permanent Discontinuation, Switch, or Change in Treatment Dose | Retrospective Cohort: From diagnosis of NT1 up to enrollment (baseline) [approximately past 5 years from enrollment]; Prospective Cohort: Up to 24 weeks | |
| Primary | Prospective Cohort: Percentage of Participants on Each Pharmacotherapy Who Permanently Discontinued Treatment, Switched Treatment, or Experienced a Change in Treatment Dose | Up to 24 weeks | |
| Primary | Prospective Cohort: Narcolepsy Symptoms Measured by the Epworth Sleepiness Scale (ESS) | Up to 24 weeks | The ESS is a validated, subjective, self-administered questionnaire used to measure daytime sleepiness. The questionnaire consists of 8 questions, each describing a common situation (e.g., sitting and reading, watching TV, sitting in a car as a passenger). Participants rate their likelihood of dozing off in each situation on a scale from 0 (would never doze off) to 3 (high chance of dozing off). The total score ranges from 0 to 24. Higher scores indicate greater daytime sleepiness. |
| Primary | Prospective Cohort: Narcolepsy Symptoms Measured by the Clinical Global Impression of Severity (CGI-S) | Up to 24 weeks | CGI-S is a 7-point scale used by clinicians to rate the severity of a participant's illness based on a global assessment of observed and reported symptoms, behaviour, and function over the past 7 days. It assesses the overall severity of mental illness relative to the clinician's experience with similar participants and uses a scale from "1= normal, not at all ill" to "7= among the most extremely ill participants". |
| Primary | Prospective Cohort: Narcolepsy Symptoms Measured by the Clinical Global Impression of Change (CGI-C) | Up to 24 weeks | CGI-C is a 7-point scale that requires the clinician to assess how much the participant's illness has improved since baseline. Ratings range from "very much improved" (1) to "very much worse" (7). |
| Primary | Prospective Cohort: Narcolepsy Symptoms Measured by the Patient Global Impression of Severity (PGI-S) | Up to 24 weeks | The PGI-S is scale for the participant to rate his/her disease severity at the time of assessment on a 5-point scale ranging from a score of 0 ("none") to 4 ("very severe"). |
1 to 10 of 53Source ClinicalTrials.gov
See all 53 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903220
GET https://conductscience.org/api/trials/v1/NCT07903220/registered?page=2